Pharmaceuticals DC $500K+ Reviewed

Barda Drive Ez-baa (ezbaa - 22-100-sol-00003)

HHS

WASHINGTON, DC

vaccines on demand host-directed therapeutics digital MCMs lung healing therapies pandemic countermeasures $500K+

Posted Apr 22, 2025

Due Oct 18, 2027

Description

The BARDA DRIVe EZ-BAA (EZ-BAA-22-100-SOL-00003), issued by HHS, solicits research and development proposals across multiple Areas of Interest (AOIs) focused on medical countermeasures, including ReDIRECT, Lab at Home, Digital MCMs, Host-Directed Therapeutics, Healing Lungs, DRIVe Forward, Vaccines on Demand, ReBooT, Host-Based Diagnostics, and REPAIR. These AOIs target innovative solutions for diagnostics, therapeutics, vaccines, and related technologies to address public health threats. Eligible bidders include biotech firms, pharmaceutical companies, academic researchers, and medical device developers with relevant expertise in advanced biomedical R&D.

A strong match for healthcare vendors

Curated for medical & healthcare suppliers

Why we classified this as medical

BARDA DRIVe EZ-BAA from HHS targets medical countermeasures (MCMs) with AOIs like Digital MCMs, Host-Directed Therapeutics, Healing Lungs, Vaccines on Demand, and ReBooT, directly involving pharmaceuticals, vaccines, and therapeutics for public health emergencies. The organization's focus on biomedical advanced research and development underscores its relevance to medical vendors in these areas.

View Original Source

Save for Later

Send to Pipeline

Closing date unconfirmed

This bid lists a closing date of Oct 18, 2027, which is more than a year out — almost certainly a data error from the source. Treat the deadline as unknown.

Please confirm the actual deadline on the original source before you rely on it.

Check the source